November 28, 2021 23:39 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tripura civic polls counting: BJP leads comfortably, wins 19 wards | Arvind Kejriwal slams critics for taking dig at his Punjab poll promise of monthly 1k transfer to all women | India registers 8,774 new COVID-19 cases amid Omicron variant scare | Maharashtra CID to quiz Param Bir Singh next week | Tripura civic polls counting on, BJP takes early leads, high stakes for TMC

Two doses of India's COVAXIN is 50 percent effective against symptomatic COVID-19: Study

New Delhi: The first real-world assessment of BBV152, a COVID-19 vaccine developed in India, known as COVAXIN in the country, suggests that two vaccine doses result in 50 percent effectiveness against symptomatic COVID-19.

Covaxin 77.8 pct effective against COVID-19: Lancet study

London: Interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India and known as Covaxin, reports that two doses offer 77.8% protection against symptomatic COVID-19, finds Lancet study.

Hong Kong approves persons vaccinated with Covaxin for inbound travel

New Delhi/UNI: Travellers who have received both doses of Covaxin are now eligible for inbound travel to Hong Kong as the country has included the India-made COVID-19 vaccine into its list of approved vaccines.

UK to recognise India's Covaxin, no quarantine required for fully vaccinated travellers

London/IBNS: Britain on Monday said it would give approval to India's indigenous COVID-19 vaccine-Covaxin-and travellers inoculated with both the shots will not be required to quarantine, media reports said.

Bharat Biotech's US partner files request for paediatric use of Covaxin

New Delhi/UNI: Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, has submitted a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the Covid-19 jab for paediatric use.

Chinese vax took longer than COVAXIN to get approval, says WHO

New Delhi/IBNS: Covaxin did not take the longest to get the World Health Organization's (WHO) approval for Emergency Use Listing, according to Chief Scientist Dr Soumya Swaminathan.

Bharat Biotech's COVAXIN gets WHO approval

New Delhi/IBNS: The World Health Organization (WHO) has given emergency use approval to Bharat Biotech's Covaxin, sources said Wednesday, clearing the way for the 'made-in-India' vaccine to get recognised by other nations and Indians inoculated with the shot would no longer need to self-quarantine or face restrictions when going abroad.

Oman approves India's Covaxin for travel without need for quarantine

Muscat/IBNS: The Government of the Sultanate of Oman on Wednesday approved Indian-made Covaxin to the list of allowed COVID-19 vaccines for travel to the country without quarantine.

Covaxin: WHO seeks 'additional clarifications', no emergency use nod given so far

New Delhi/UNI: The process to include indigenously developed COVID-19 vaccine, Covaxin, in Emergency Use Listing (EUL) of World Health Organisation (WHO) is delayed by a week as the Technical Advisory Group of the UN body has sought "additional clarifications" from the vaccine manufacturer.

Bharat Biotech's Covaxin recommended for use in children below 18 years

New Delhi/IBNS: An expert panel on Tuesday recommended Bharat Biotech's Covaxin to be administered on children between the ages of two and 18.

Decision on Covaxin's clearance next: WHO

New Delhi/IBNS: The World Health Organisation (WHO) on Tuesday said it will announce its decision on clearance of India's indigenously developed Covaxin next week when the UN agency and an independent group of experts meet.

WHO's clearance to Bharat Biotech's Covaxin delayed: Reports

New Delhi/IBNS: The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the COVID vaccine developed in India by pharmaceutical company Bharat Biotech, media reports said.

India won't buy 'expensive' Moderna, Pfizer Covid-19 shots as local production soars: Report

New Delhi/IBNS: India would not buy Covid-19 vaccines from foreign producers  Pfizer/BioNTech and Moderna as domestic production of the shots has increased manifold, Reuters reported citing sources.

WHO approval for Covaxin likely by month-end, says Niti Aayog

New Delhi/IBNS: The World Health Organisation's emergency approval for indigenously made Covid-19 jab, Covaxin, can come by the end of September, said Dr VK Paul, chairman of the National Expert Committee on Vaccine Administration, according to media reports.

COVID-19: India reports 25,404 new infections, 339 deaths in 24 hours

New Delhi/UNI/IBNS: India logged 25,404 new cases and 339 deaths due to the COVID-19 in the last 24 hours, the Union Health Ministry said Tuesday.